Last Price Today's Change   Day's Range   Trading Volume
1.03   +0.01 (0.98%)  1.01 - 1.04  1,351,400
Trade this stock and receive a FREE I3investor T-shirt after 5 trades. Find out more.


Market Cap: 682 Million
NOSH: 662 Million
Avg Volume (4 weeks):666,205
4 Weeks Range:0.955 - 1.05
4 Weeks Price Volatility (%):
52 Weeks Range:0.925 - 3.43
52 Weeks Price Volatility (%):
Average Price Target: 1.52
Price Target Upside/Downside: +0.49
Stamp duty exempted for year 2019

Financial Highlight

Latest Quarter | Ann. Date 31-Dec-2018 [#4]  |  18-Feb-2019
Next QR | Est. Ann. Date: 31-Mar-2019  |  28-May-2019
T4Q P/E | EY: 14.28  |  7.00%
T4Q DY | Payout %: 4.50%  |  64.23%
T4Q NAPS | P/NAPS: 0.73  |  1.41
T4Q NP Margin | ROE: 9.55%  |  9.88%


Date Subject
14-Dec-2018 Technical Analysis - CCM Duopharma Biotech
14-Dec-2018 M+ Online Technical Focus - 14 Dec 2018
14-Dec-2018 Daily Market Update - 14 Dec 2018 (CCMDBIO, SERBADK)
29-Nov-2018 CCM Duopharma Biotech Bhd - Outlook Remains Stable
26-Oct-2018 预算案值得关注的个股(四)- 医疗保健
26-Oct-2018 Mplus Market Pulse - 26 Oct 2018
26-Oct-2018 PublicInvest Research Headlines - 26 Oct 2018
05-Sep-2018 CCM Duopharma Biotech Bhd - Expecting Stronger 3Q18 Earnings
28-Aug-2018 CCM Duopharma Biotech Bhd - Outlook Remains Stable
27-Aug-2018 Technical Analysis - CCM Duopharma Biotech
18-Jul-2018 M+ Online Technical Focus - 18 Jul 2018
18-Jul-2018 Daily Market Update - 18 Jul 2018 (KRONO, CCMDBIO)
10-Jul-2018 CCM Duopharma Biotech - Solidifying Its No 1 Position in the Local Pharma Sector
21-Jun-2018 Technical Analysis - CCM Duopharma Biotech
08-Jun-2018 Mplus Market Pulse - 8 Jun 2018
30-May-2018 CCM Duopharma Biotech Bhd - Demand Remains Strong
30-May-2018 Mplus Market Pulse - 30 May 2018
25-May-2018 Daily Technical Highlights – (CCMDBIO, INARI)
30-Apr-2018 年产1.07亿片Flavettes维他命C.马化学药业泡腾科技领先
29-Mar-2018 CCM Duopharma Biotech Bhd - Sustainable Earnings

Business Background

CCM Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures and markets generic and over-the-counter pharmaceutical products. Its segment is engaged in manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines. The company's products include tablets, capsules, syrup, oral antibiotic, creams, hemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges and eye drop preparations.
Analyze this stock with MQ Trader system

  4 people like this.
coldeye2 why the price keep on droping??
08/08/2018 10:19
InvestmentLearning is it because EPF disposed it?
08/08/2018 11:34
thor85 Padan muka. Kedekut punya kompeni.
08/08/2018 20:42
moneypedia oww yeke kedekut....
08/08/2018 21:09
kcthai99 price is very low now
10/08/2018 06:59
chandra54 going to fly soon. more orders pouring in from govt pharm. and overseas!grab now!
14/08/2018 16:23
chandra54 More insulin orders from govt pharmacies and private. grab now !
14/08/2018 16:35
moneytrail Flying back to 1.50? Should be one of the billion market capitalization companies!!
15/08/2018 11:24
jibbie https://www.malaymail.com/s/1662860/ministry-of-health-halts-programme-providing-new-drugs-for-free

Is ccmdbio affected by this ruling?
16/08/2018 10:50
BlackWhite No more free samples
16/08/2018 21:11
thor85 Undervalued stock.
22/08/2018 19:43
Jasper Coo Good show ! Very strong... will move tomorrow and profit incoming
23/08/2018 11:28
moneytrail http://www.theedgemarkets.com/article/clarity-needed-policies-healthcare-industry

23/08/2018 14:04
Egalelity Up one day, drop three more day. Lame counter
24/08/2018 13:13
thor85 Next week qr result will be good. Early this year moh payment got problems bcoz of govt epayment system mistake. In second quarter the problem is fully solved already.Plus the new product flavettes effervescent glow is very hot in market.
25/08/2018 07:38
Stephenloo QR released
27/08/2018 18:37
necro walauwei...my ex girlfriend..
27/08/2018 19:39
Investeye Q2Q is slightly better (but lower compared previous Q). Today share price up 7% already, so further up is just a ?.. Overall it is still reasonable.
27/08/2018 20:41
Stephenloo no more show?
07/09/2018 22:02
Investeye Time to collect again at this attractive price...
08/09/2018 09:41
chandra54 Post removed. Why?
13/09/2018 14:57
jason007 sell !
13/09/2018 16:09
Romyzam On board. Need to go back 1.27 for uptrend. Cheap at current price. Today forced selling that's y can get low price. Let's see tomorrow.
13/09/2018 17:40
chandra54 yeah romyzam, will go hopless yet again. forget to smell 1.27. this prise is history
18/09/2018 13:03
chandra54 Post removed. Why?
18/09/2018 13:04
Jordan Khoo Good show ! Very strong... will move tomorrow and profit incoming
18/09/2018 15:26
Gavin Chua may i know CCMBIO's competitors ?
18/09/2018 22:57
jibbie pharmaniaga, yspsah, hovid
19/09/2018 16:38
Romyzam Nice recovery today. More to come tomorrow. Really hope back to 1.27 and above...
19/09/2018 18:28
chandra54 Post removed. Why?
25/09/2018 10:15
Romyzam Cool Chandra. Now accumulation time. I bought total 100k shares from 1.15 to 1.19. If break 1.14 again then cut lo
25/09/2018 11:58
Romyzam Nicely back to 1.26 today.
26/09/2018 13:16
Romyzam Sold back all 1.23 to 1.26. Good luck those still holding. Good counter but too slow. Thanks ccmdbio for the quick bucks.
02/10/2018 19:14
Investeye Take opportunity to accumulate more based on EPF kept accumulating recently. In fact after holding some lots for 1.5 yrs, it is still gaining at this price ( due to bonus 4:3 issuing 15 maths ago)
03/10/2018 20:24
04TSH Interesting feedbacks and advices guys
04/10/2018 16:09
Romyzam Buy back 1.12. Cheap sale.
11/10/2018 12:05
Stephenloo Declared 1.5 cent dividen
22/10/2018 19:29
YKLIEW Bought 1-28 down 20 sen but get 1.5 sen dividend. Terrible investment yo
02/11/2018 21:45
moneytrail Collect for long term, consistent profit this 2 years. Factory expansion to bear fruit 2020. Niche product and stem cells product, hope to give higher margin to offset margin erosion from competitive generic drugs.
03/11/2018 15:46
jinghee Will the government budget benefit this company?
08/11/2018 20:55
Hafid people are selling
15/11/2018 16:16
kmwong8711 Today quarter results out??
16/11/2018 10:55
necro I must said recent acquisition & ventures were uninteresting to investor, too many drug & substances in pipeline. Investor dont understand of what is the drug is going to do with Malaysia market.

Asean is not like Singapore, Japan or Korea where the country spend 7% of GDP for healthcare budget, Malaysia for example is only use of 3% GDP for healthcare budget.

Malaysia healthcare priority budgeting only for "3 serangkai" diseases which diabetes, high blood pressure & heart diseases. Disease like autoimmune, chronic kidney disease(ckd), obstetric &, gynaecology using advance medication were too expensive for government to used.

Hopefully CEO does not to eager to pursuing pipeline quantity but focus more on quality, he must realise that that CCMDBIO is conglomerates not science lab where he can test new drug or substances onto Malaysian people.
22/11/2018 09:55
moneytrail Good resukts
28/11/2018 22:56
Tete7893 Luckily run early.
26/12/2018 17:45
Yi Heng 0.94 all in
22/01/2019 19:22
Nicholasming91 Can buy wow
18/02/2019 19:01
Yi Heng yes, dividend 4 sen if approved
18/02/2019 19:23
Investeye CCM Duopharma Biotech Bhd’s fourth quarter net profit rose 18.45% to RM14.37 million from RM12.13 million a year ago, due to higher revenue and changes in accounting policies arising from adoption of the Malaysian Financial Reporting Standards 9 (MFRS 9).
Earnings per share for the quarter ended Dec 31, 2018 rose to 2.17 sen from 1.86 sen.
Quarterly revenue was up 3.01% to RM115.63 million, from RM112.25 million previously, the group said in a filing with Bursa Malaysia.
CCM Duopharma has declared a final dividend of four sen, bringing total payout for FY18 to 5.5 sen, as against 3.64 sen in FY17.
The group has also proposed that the dividend reinvestment plan would apply to the final dividend.
For FY18 as a whole, CCM Duopharma’s net profit increased 12.19% to RM47.64 million or 7.26 sen per share from RM42.46 million or 6.52 sen per share last year, while revenue grew 6.57% to RM498.72 million from RM467.99 million.
On prospects, the group said it sees opportunities from the increase in allocation for health services to RM29 billion in Budget 2019 including RM10.8 billion to restore clinics and hospitals as well to buy medicine and medical equipment.
“The group will also continue its foray into the specialty products as one of its strategies moving forward to create a pool of niche products,” said CCM Duopharma, adding that it has recently received registration approval for Erysaa, an erythropoeitin product.
Barring any unforeseen circumstances, the group expects to achieve satisfactory results in FY19.
18/02/2019 22:08
shpg22 Liquidity has deteriorated quite rapidly, still able to give 4cents dividend. Good management
18/02/2019 22:49


360  342  511  653 

Top 10 Active Counters
 SAPNRG 0.3050.00 
 ARMADA 0.225-0.01 
 JAG 0.055-0.025 
 BORNOIL 0.0450.00 
 HSI-H4Y 0.215-0.08 
 HSI-C3W 0.375+0.08 
 EDUSPEC 0.030.00 
 IRIS 0.14+0.01 
 SEACERA 0.315-0.015 
 BARAKAH 0.125-0.005 


1. Investment Bloggers Day 2019 MQ Trader Announcement!
Partners & Brokers